Shibani Pati, MD, PhD
Download a curriculum vitae [pdf file]
I am a vascular biologist with an interest in the role of endothelial dysfunction and vascular compromise in the pathogenesis of human disease. My specific areas of investigation involve the use of stem cells and novel resuscitative modalities that can mitigate endothelial dysfunction in traumatic injury.
Abnormalities in vascular permeability leading to inflammation, tissue edema, and end-organ dysfunction significantly contribute to the morbidity and mortality associated with a number of human disease processes. For example, although a number of factors contribute to the high mortality and morbidity associated with traumatic brain injury (TBI), the development of cerebral edema with brain swelling remains one of the most significant predictors of outcome. Similarly both hemorrhagic shock and septic shock are characterized by abnormal vascular permeability, which contributes to the development of shock-associated acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Despite the clear importance of abnormal vascular permeability in a number of human disease processes, there exists no therapeutic modality in current use to attenuate it.
Cellular Therapy and Cell Production Lab
We have embarked on an endeavor to produce clinical grade Mesenchymal stem cells (MSCs) in partnership with our parent organization Blood Systems Inc. in Tempe, Arizona. The lab at BSRI is the scientific core of the program and the clinical production core is in Tempe, AZ led by Dr. Frank Nizzi, VP of Clinical Services and Clinical Director of Cellular Therapies at Blood Systems Inc.. The goal of this program is to produce cells for clinical trials and long term commercialization.
CIRM-BSRI Conference on Cellular Therapies in Trauma and Critical Care Medicine
We have now organized and hosted two meetings that have been focused upon cellular therapies in trauma and critical care. The first was held in 2012 and the most recent meeting was held in September, 2015. The website for the meeting is www.cttacc.org. The goal of this meeting is to bring together the expertise and input of blood bankers, clinicians running trials, basic scientists, companies, FDA, NIH, AABB, and the DOD representatives to discuss existing barriers in the translation of cell therapies in trauma and critical care medicine, a field with few therapeutic options. The areas covered spanned translationally relevant topics such as cell sourcing, cell expansion, cell storage, safety, funding, pre-clinical studies and clinical trials. Our speakers had diverse expertise and knowledge in these areas. Our target audience included clinicians, physician- scientists, and basic scientists who are currently working in or anticipate working in the field of cellular therapeutics in critically ill patients. The next meeting is scheduled for early 2017.